Richard E. Lowenthal - 03 Jan 2023 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
05 Jan 2023, 16:00:30 UTC
Previous filing
10 Nov 2022
Next filing
04 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +1,100,000 $0.000000 1,100,000 03 Jan 2023 Common Stock 1,100,000 $8.42 Direct F1
transaction SPRY Stock option (right to buy) Award $0 +350,000 $0.000000 350,000 03 Jan 2023 Common Stock 350,000 $8.42 By spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.